- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03974477
Study With an Innovative Equipment to Monitor and Control SALT During Cooking (iMC_SALT)
Randomized Controlled Trial With SALT CONTROL H - Impact on Individual Sodium and Sodium to Potassium Ratio Excretion
In this study, the researchers will evaluate the efficacy of an intervention using the SALT CONTROL H instrument (an innovative equipment to monitor and control salt) in workers at the University of Porto to reduce dietary salt intake. This is a randomized clinical trial with intervention conducted according to good clinical practice guidelines.
The researchers will randomize 260 workers who meet the eligibility criteria and are enrolled in occupational health appointments. Prior to the intervention, the informed consent of the participants will be obtained and those who agree to participate will be allocated randomly in one of the two arms of the study (control or intervention), with balance of baseline characteristics (sex and hypertension).
The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content, will be used an illustrative video and recipes with an adequate salt content; use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about "The new Food Wheel, a guide to the daily food choice!".
Control Group: No intervention will be carried out except the provision of a leaflet on "The new Food Wheel, a guide to the daily food choice!" to the participants.
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention analysis will cover the following domains: urinary sodium excretion corresponding to a 24 hour urine collection as a proxy for salt intake; 24-hour urinary potassium excretion, sodium:potassium ratio, systolic and diastolic blood pressure, and anthropometric measurements. Urine samples will be collected according to standardized procedures and analyzed by a certified laboratory. Secondary data such as satisfaction questionnaire, daily use of equipment, iodine analysis of salt used and excreted in urine 24h, hydration status, analysis of quality of life and quality of diet will also be analyzed, as well as intestinal microbiota.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Porto, Portugal, 4200-465
- Carla Gonçalves
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults (> 18 years)
- Eat frequently cooked meals at home (> 4 days a week, of which at least 3 Sundays / month)
- Have an occupational health appoitments at São João Hospital
- Reported motivation to control salt consumption
Exclusion Criteria:
- Pregnant
- Subjects with kidney disease,
- Subjects with active infection with an impact on renal function,
- Subjects with urinary incontinence,
- Subjects with acute coronary syndrome,
- Subjects with severe liver disease;
- Subjects with heart failure;
- Subjects who do not use salt for cooking;
- Subjects with hypotension;
- Subjects that work at Faculty that are the Sponsor of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention
The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H.
A leaflet will also be delivered about "The new Food Wheel, a guide to the daily food choice!".
|
Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
|
NO_INTERVENTION: Control
No intervention will be carried out except the provision of a leaflet on "The new Food Wheel, a guide to the daily food choice!" to the participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline 24h urinary sodium excretion at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Sodium excretion as a proxy of dietary salt intake
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline 24h urinary potassium excretion at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Urinary potassium excretion as a proxy of dietary potassium intake
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Systolic Blood Pressure at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Systolic blood pressure
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Diastolic Blood Pressure at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Diastolic blood pressure
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Hydration Status at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
urinary osmolality (mOsm/kg)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Perception of quality of life at during and after intervention
Time Frame: Baseline, at 8th intervention week, and 6 months after intervention
|
Questionnaire WHOQOL-BREF, results from 0 to 100, higher values represent better perception of quality of life
|
Baseline, at 8th intervention week, and 6 months after intervention
|
Change from Baseline Culinary competences at during and after intervention
Time Frame: Baseline, at 8th intervention week, and 6 months after intervention
|
Questionnaire, questions scales from 1 to 6 according to culinary competences, higher values represent better culinary competences
|
Baseline, at 8th intervention week, and 6 months after intervention
|
Change from Baseline Intestinal Microbiota at after intervention
Time Frame: Baseline and at 8th intervention week
|
OTU (operational taxonomy unit) analysis (%)
|
Baseline and at 8th intervention week
|
Change from Baseline Diet Quality at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
HDI (Healthy Diet Indicator), HDI-2015 was calculated as the sum of 7 components (range 0-7) and was classified as follows: high adherence (met 6-7 components), moderate adherence (met 4-5 components), and low adherence (met 0-3 components)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Knowledges, attitudes and behaviours about salt at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Questionnaire on Knowledge, Attitudes, Behavior toward Dietary Salt and Health from PAHO (n and %)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Weight at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Weight in kilograms
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Height at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Height in meters
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Fat Mass and Fat Free Mass at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Fat mass (in kg), Fat free mass (in kg)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Extra and intra cellular water at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Extra and intra cellular water, basal metabolic rate
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Extra and intra cellular water at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Extra and intra cellular water (in kg)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Change from Baseline Basal Metabolic Rate at during and after intervention
Time Frame: Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Basal metabolic rate (in kcal)
|
Baseline, at the 4th and 8th intervention weeks, and 6 months after intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Carla Gonçalves, PhD, Researcher
Publications and helpful links
General Publications
- Goncalves C, Abreu S, Padrao P, Pinho O, Graca P, Breda J, Santos R, Moreira P. Sodium and potassium urinary excretion and dietary intake: a cross-sectional analysis in adolescents. Food Nutr Res. 2016 Apr 11;60:29442. doi: 10.3402/fnr.v60.29442. eCollection 2016.
- Goncalves C, Monteiro S, Padrao P, Rocha A, Abreu S, Pinho O, Moreira P. Salt reduction in vegetable soup does not affect saltiness intensity and liking in the elderly and children. Food Nutr Res. 2014 Oct 6;58. doi: 10.3402/fnr.v58.24825. eCollection 2014.
- Moreira P, Sousa AS, Guerra RS, Santos A, Borges N, Afonso C, Amaral TF, Padrao P. Sodium and potassium urinary excretion and their ratio in the elderly: results from the Nutrition UP 65 study. Food Nutr Res. 2018 Feb 27;62. doi: 10.29219/fnr.v62.1288. eCollection 2018.
- Goncalves C, Silva-Santos T, Abreu S, Padrao P, Graca P, Oliveira L, Esteves S, Norton P, Moreira P, Pinho O. Innovative equipment to monitor and control salt usage when cooking at home: iMC SALT research protocol for a randomised controlled trial. BMJ Open. 2020 May 17;10(5):e035898. doi: 10.1136/bmjopen-2019-035898.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- iMCSALT19-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on SALT CONTROL H equipment to control and monitor salt during cooking process
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
Children's Oncology GroupRecruitingRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingB Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia
-
National Cancer Institute (NCI)RecruitingDown Syndrome | B Acute Lymphoblastic Leukemia | B Lymphoblastic LymphomaUnited States, Puerto Rico, Australia, Canada, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingB Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute LeukemiaUnited States, Puerto Rico, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI); EsPhALL Network/ BFM Study GroupRecruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Switzerland